HOME >> MEDICINE >> NEWS
New generation contact lenses cut risk of severe eye infection

Sleeping in contact lenses carries a significant risk of severe eye infection (keratitis), but the new generation silicone hydrogel lenses cut that risk fivefold, finds research in the British Journal of Ophthalmology.

The findings are based on a year long study of patients attending the Royal Eye Hospital in Manchester, UK, with acute eye problems.

All those wearing contact lenses were asked to supply details of lens hygiene, type, and pattern of wear, including whether they slept in them.

Specialists scored eye problems on the cornea according to their severity, a score above 8 denoting severe keratitis. Eighty were scored below 8, defined as 'non-severe keratitis,' and 38 were scored above.

Among the 80 who scored below 8, 18 slept in their lenses. Among the 38 with severe keratitis, 9 did so.

Four types of lenses were studied - rigid, hydrogel daily disposable, hydrogel, and silicone hydrogel. There were no differences in risk of severe keratitis between the different types of lenses when they were worn during the day.

But the risk of severe keratitis rose when lenses were slept in, and there were some differences between lens types.

Rates were 96 per 10,000 wearers a year for hydrogel lenses, compared with almost 20 per 10,000 wearers a year for silicone hydrogel lenses - a fivefold difference.

Almost 3 million people wear contact lenses in the UK, around 55,000 of whom live in the catchment area served by the hospital, including 30,000 hydrogel lens wearers and 1700 silicone hydrogel lens wearers.

But those wearing hydrogel lenses while they slept were five times more likely to develop severe keratitis than those wearing silicone hydrogel lenses.

"Those who choose to sleep in lenses should be advised to wear silicone hydrogel lenses, which carry a five times decreased risk of severe keratitis for extended wear compared with hydrogel lenses," conclude the authors.


'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ Specialty Journals
21-Mar-2005


Page: 1

Related medicine news :

1. Genetics important in age-related macular degeneration
2. Gene for age-related macular degeneration discovered by Yale researchers
3. UCSD-Utah team develops mouse model to test therapies for macular degeneration
4. Next generation body scanner launched by the University of Manchester
5. Penn study shows how next-generation diabetic drugs could work more selectively
6. Get ready for next generation surround sound
7. Macular degeneration patients benefit from self-management training
8. New programme will train the next generation of health leaders
9. Pegaptanib provides benefit for neovascular age-related macular degeneration
10. New clue to nerve growth may help regeneration efforts
11. Mayo Clinic researchers announce promising next generation treatments for multiple myeloma

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New generation contact lenses cut risk severe eye infection

(Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
(Date:6/18/2013)... Daily Gossip Magazine has always kept its readers entertained ... , The magazine has decided to prepare readers for the ... recipe every week . , According to Daily Gossip ... readers who are looking to get insights into this type ... anabolic food is almost entirely based on healthy, yet tasteful ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 SEATTLE, WA—A ... Farms of Fairview, Oregon, claiming he fell ill with ... berry and pomegranate seed blend. The complaint was ... by Marler Clark, the Seattle-based law firm that has ... , According to the complaint, Brian Brothers consumed “Townsend ...
(Date:6/18/2013)... Warner, NH (PRWEB) June 18, 2013 ... rugged, submersible, battery powered, stand-alone device which can be ... The new stainless steel enclosure of the Temp1000IS comes ... device interfaces with the IFC400 (sold separately) ... docking station for full communications. No more removal of ...
(Date:6/18/2013)... Senior drug regulatory officials from mainland China and Taiwan ... first time in the U.S.—the need for more collaboration between ... in a timely manner. Representatives from the Taiwan and mainland ... and processes in drug review during the Convergence in ... DIA 2013 49th Annual Meeting . , While ...
Breaking Medicine News(10 mins):Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
(Date:6/18/2013)... , Safinamide significantly improves ... as add-on to levodopa Safinamide is ... in fluctuating PD patients as add-on to levodopa ... ("Newron"), a research and development company focused on ... Zambon S.p.A., a pharmaceutical company strongly committed to ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: